Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report

Table 1 Randomized trials in metastatic bladder cancer

Regimen	No of patients	OR (%)	mOS (mo)	P value
MVAC	246	36	12.5	< 0.01
Cisplatin		11	8.2
MVAC	110	65	12.6	< 0.05
CISCA		46	10
MVAC	169	59	12.5	> 0.05
FAP		42	12.5
MVAC	263	58	14.1	> 0.05
HD-MVAC		72	5.5
MVAC	408	46	14.8	> 0.05
GC		50	13.8
MVAC	220	54	14.2	< 0.05
DC		37	9.3
MVAC	85	40	14.2	> 0.05
PC		28	13.8
GC	627	46	12.8	> 0.05
GCP		57	15.7

MVAC: Methotrexate, vinblastine, doxorubicin, and cisplatin; CISCA: Cyclophosphamide, cisplatin, and doxorubicin; FAP: 5-Fluorouracil, interferon-alpha-2b, and cisplatin; HD-MVAC: High-dose MVAC; GC: Gemcitabine and cisplatin; DC: Docetaxel and cisplatin; PC: Paclitaxel and carboplatin; GCP: Gemcitabine, cisplatin, and paclitaxel; OR: Overall response; mOS: Median overall survival.

Table 2 Second-line chemotherapy in metastatic bladder cancer

Regimen	No of patients	OR% (95%CI)
Paclitaxel	31	10 (0-26)
Docetaxel	30	13 (4-30)
Ifosfamide	56	20 (10-32)
Gemcitabine	35	20 (10-36)
Paclitaxel and carboplatin	44	16 (7-30)
Vinflunine	51	18 (8-31)
Pemetrexed	13	8 (NR)
Pemetrexed	47	28 (16-43)

OR: Overall response; CI: Confidence interval; NR: Not reported.

Table 3 Selected trials of anti-HER2 agents in advanced bladder cancer

Regimen	Phase	No of patients	Prior chemotherapy	Target enrichment	OR (%)	mOS (mo)
Carboplatin/ paclitaxel/ gemcitabine/trastuzmab	I/II	57	No	Yes	70	14.1
Lapatinib	II	59	Yes	No	1.7	4.5
Lapatinib maintenance after first-line chemotherapy	II/III	116	No	Yes	14	12.6

OR: Overall response; mOS: Median overall survival.